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Research Article
IMiDs induce FAM83F degradation via an interaction with
CK1α to attenuate Wnt signalling
Karen Dunbar , Thomas J Macartney, Gopal P Sapkota
Immunomodulatory imide drugs (IMiDs) bind CRBN, a substrate
receptor of the Cul4A E3 ligase complex, enabling the recruitment
of neo-substrates, such as CK1α, and their degradation via the
ubiquitinproteasome system. Here, we report FAM83F as such a
neo-substrate. The eight FAM83 proteins (A-H) interact with and
regulate the subcellular distribution of CK1α. We demonstrate that
IMiD-induced FAM83F degradation requires its association with
CK1α. However, no other FAM83 protein is degraded by IMiDs. We
have recently identified FAM83F as a mediator of the canonical Wnt
signalling pathway. The IMiD-induced degradation of FAM83F at-
tenuatedWnt signalling in colorectal cancer cells and removed CK1α
from the plasma membrane, mirroring the phenotypes observed
with genetic ablation of FAM83F. Intriguingly, the expression of
FAM83G, which also binds to CK1α, appears to attenuate the IMiD-
induced degradation of CK1α, suggesting a protective role for
FAM83G on CK1α. Our findings reveal that the efficiency and extent
of target protein degradation by IMiDs depends on the nature of
inherentmultiprotein complex in which the target protein is part of.
DOI 10.26508/lsa.202000804 | Received 1 June 2020 | Revised 11 December
2020 | Accepted 11 December 2020 | Published online 23 December 2020
Introduction
Thalidomide, the first immunomodulatory imide drug (IMiD), ini-
tially came to prominence as a treatment for morning sickness in
the 1950s but was quickly abandoned after it became apparent that
consumption of thalidomide in the first trimester of pregnancy
caused foetal abnormalities, predominately manifesting as limb
deformities (Vargesson, 2015). Despite these severe teratogenic
effects, the mechanism of action remained elusive for several
decades until it was found that IMiDs hijack the ubiquitin–
proteasomal system to facilitate protein degradation of non-native
substrates, which have been termed “neo-substrates” (Kronke et al,
2014). IMiDs act as molecular glues by binding to both neo-
substrates and a hydrophobic binding pocket of cereblon
(CRBN), which is a substrate receptor of the Cul4A–E3 ligase
complex. This brings the neo-substrates into close proximity to the
Cul4A–ROC1–DDB1–CRBN E3 ligase complex (known as Cul4ACRBN),
thereby facilitating their ubiquitylation and subsequent protea-
somal degradation (Kronke et al, 2014). Recently, two distinct de-
rivative analogues of thalidomide, lenalidomide (Rajkumar et al,
2005) and pomalidomide (Miguel et al, 2013), have been repurposed
for the effective treatment of multiple myeloma. Their efficacy has
been attributed to the induced degradation of the zinc-finger
transcription factors IKZF1 and IKZF3 which have key roles in
B- and T-cell biology (Kronke et al, 2014).
Whereas themajority of identified IMiD neo-substrates appear to
be zinc-finger transcription factors (Kronke et al, 2014; An et al, 2017;
Sievers et al, 2018), lenalidomide has also been shown to induce the
degradation of the serine/threonine kinase CK1α (Kronke et al,
2015). Casein kinase 1 isoforms (α, α-like, δ, ε, γ1, γ2, and γ3) are a
family of serine/threonine protein kinases which control many
cellular processes, including Wnt signalling, circadian rhythms,
calcium signalling, cell division, and responses to DNA damage
(Cheong & Virshup, 2011; Cruciat, 2014; Jiang et al, 2018; Philpott et al,
2020). Lenalidomide binds to a β-hairpin loop in the kinase N-lobe
of CK1α, bringing it into proximity of the Cul4ACRBN complex to
facilitate its ubiquitylation and subsequent proteasomal degra-
dation (Petzold et al, 2016). The degradation of CK1α is thought to
cause the efficacy of lenalidomide in the treatment of myelodys-
plastic syndromes (MDS) (List et al, 2006). MDS are a group of blood
cancers, of which a subtype are caused by deletion of chromosome
5q (del(5q)) (List et al, 2006). In such cancers, deletion of a region of
chromosome 5q results in CK1α haploinsufficiency through loss of
the CSNK1A1 gene (Kronke et al, 2015), thereby sensitizing cells
against further degradation of CK1α by lenalidomide.
Historically, CK1 isoforms were thought to be monomeric, un-
regulated, and constitutively active, but there is now accumulating
evidence that a family of previously uncharacterised proteins, the
FAM83 proteins, act as anchors for several of the CK1 isoforms (α,
α-like, δ, and ε) and can alter their subcellular localisation in re-
sponse to specific stimuli (Bozatzi et al, 2018; Fulcher et al, 2018). The
FAM83 family is composed of 8 members, termed FAM83A-H, which
share a conserved N-terminal domain of unknown function 1669
(DUF1669), which mediates the interaction with different CK1 iso-
forms (Fulcher et al, 2018). Each member binds to different CK1
isoforms with varying specificity and affinity (Fulcher et al, 2018). All
FAM83 proteins interact with CK1α, whereas FAM83A, B, E, and H also
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interact with CK1δ and ε (Fulcher et al, 2018). Whereas the FAM83
family remains largely uncharacterised, roles for specific FAM83–
CK1α complexes have been established in mitosis (Fulcher et al,
2019; Fulcher & Sapkota, 2020) and canonical Wnt signalling (Bozatzi
et al, 2018; Wu et al, 2019; Dunbar et al, 2020). Given the reports of
IMiD-induced degradation of CK1α, we sought to establish the effect
of IMiDs on the stability of FAM83 proteins and different FAM83–
CK1α complexes.
Results
IMiDs selectively degrade FAM83F protein
Lenalidomide, which is used as a therapeutic agent in patients with
del(5q) MDS, causes CK1α degradation (Kronke et al, 2015). In MV4.11
cells, which are derived from B-myelomonocytic leukaemia, the
thalidomide derivatives lenalidomide, pomalidomide, and iber-
domide led to robust degradation of IKZF1, but only lenalidomide,
and to a lesser extent pomalidomide, led to partial degradation of
CK1α (Fig 1A). The efficacy of lenalidomide-induced CK1α degra-
dation in other cell lines, including THP-1 monocytes, HCT116 co-
lorectal cancer, A549 lung adenocarcinoma, DLD-1 colorectal
cancer, PC-3 prostate cancer, and HaCaT keratinocyte cell lines
were more variable with the most substantial CK1α degradation
observed in HCT116, DLD-1, and HaCaT cells (Fig 1B). As the FAM83
proteins exist in complexes with CK1α (Fulcher et al, 2018), we
sought to test the effect of the IMiDs thalidomide, lenalidomide,
and pomalidomide on FAM83 protein levels in THP-1, HCT116, A549,
DLD-1, PC-3, HaCaT, U2OS, HEK-293, ARPE-19, SH-SY5Y, G-361, and SK-
MEL-13 cell lines. Both lenalidomide and pomalidomide but not
thalidomide induced a robust reduction in FAM83F protein abun-
dance in HCT116, DLD-1, and HaCaT cells, whereas in the other
tested cell lines FAM83F protein was not detectable (Figs 1C and D
and S1A and B). None of the IMiDs led to any detectable reduction in
FAM83B, FAM83D, FAM83G, or FAM83H protein abundance in any cell
line tested (Figs 1C and S1A and B). Currently, no reliable antibodies
exist for the detection of endogenous FAM83A, FAM83C, and FAM83E
proteins, limiting their assessment in this assay. A modest deg-
radation of CK1αwas observedwith lenalidomide treatment in THP-1,
HCT116, A549, HEK-293, SH-SY5Y, andG-361 cells (Figs 1C andD andS1A
and B), whereas no consistent change in either CK1δ or CK1ε protein
levels was detected following IMiD treatment (Figs 1C and S1A and B).
As expected, lenalidomide and pomalidomide caused robust deg-
radation of IKZF1 in THP-1 cells, whereas no IKZF1 was detected in
non-hematopoietic cells (Fig 1C). ZFP91, a pomalidomide specific
neo-substrate (An et al, 2017), was degraded upon pomalidomide
treatment in all cell lines, whereas its expressionwas undetectable in
THP-1 cells (Figs 1C and S1A and B).
Further characterisation of FAM83F degradation in HCT116 and
DLD-1 cells revealed a time and dose dependence on lenalidomide
and pomalidomide treatment, with optimal degradation occurring
after 24-h treatments with 10 μM IMiD (Figs 1E and F and S2A and B).
Novel heterobifunctional compounds that recruit target proteins to
CRBN through an IMiD moiety, such as dTAG-13, lead to target
protein degradation through Cul4ACRBN (Nabet et al, 2018). We found
that dTAG-13 was incapable of degrading CK1α, FAM83F, and ZFP91 in
HCT116 and DLD-1 cells, confirming the utility of certain IMiD
moieties for development of bivalent protein degraders (Fig S2C)
(Nabet et al, 2018).
FAM83F and CK1α protein abundance is reduced at the plasma
membrane upon IMiD treatment
Endogenous FAM83F is predominately located at the plasma
membrane as observed by immunofluorescence of HCT116 cells in
which a GFP tag was knocked in homozygously at the N-terminus of
the FAM83F gene (GFP/GFPFAM83F cells) (Figs 2A, S3A, and S4A)
(Dunbar et al, 2020). Upon treatment of HCT116 GFP/GFPFAM83F cells
with pomalidomide, the GFP signal was lost from the plasma
membrane (Fig 2A). Under basal conditions, CK1α, which can in-
teract with all eight FAM83 proteins, is distributed throughout the
cell, and so we were unable to determine the effect of pomali-
domide on membranous CK1α by immunofluorescence (Fig 2A).
However, when we analysed subcellular fractions of DLD-1 wild-
type cells, we observed that FAM83F was predominately present in
the membrane fraction, with a small proportion also observed in
the nuclear fraction, whereas CK1α is present in cytoplasmic, nu-
clear, and membrane fractions (Fig 2B). When DLD-1 wild-type cells
were treated with pomalidomide, a reduction in the levels of both
FAM83F and CK1α protein was observed in the membrane fraction,
whereas CK1α protein levels in the cytoplasmic and nuclear frac-
tions did not change relative to untreated DLD-1 wild-type cells (Fig
2B). FAM83F interacts with CK1α and is responsible for delivering it
to the plasma membrane (Dunbar et al, 2020). Interestingly, the
pomalidomide-induced reduction of CK1α protein from the plasma
membrane in DLD-1 wild-type cells was comparable with the stable
reduction of membranous CK1α observed in FAM83F-knockout
(FAM83F−/−) DLD-1 cells, generated using CRISPR/Cas9 genome
editing, in the absence of pomalidomide treatment (Figs 2B, S3A,
and S4B). In the absence of FAM83F, pomalidomide treatment did
not induce any detectable degradation of CK1α from the membrane
fraction in DLD-1 FAM83F−/− cells, confirming that the IMiD-induced
loss of CK1α protein from the plasma membrane is mediated by
FAM83F.
IMiD-induced degradation of FAM83F requires interaction with
CK1α
The robust degradation of FAM83F by lenalidomide and pomalidomide
in several cancer cell lines prompted us to explore whether this
degradation was mediated through the association of FAM83F with
CK1α. Several conserved residues within the DUF1669 domains of
FAM83 proteins have been identified as critical mediators of the
FAM83-CK1 interaction (Fulcher et al, 2018). For FAM83F,mutation of two
phenylalanine residues at positions 284 and 288 to alanine would be
predicted to abolish association with CK1α (Dunbar et al, 2020). As
expected, FAM83F co-precipitated with CK1α in CK1α immunoprecipi-
tates (IPs) from HCT116 wild-type cells but not from FAM83F-knockout
(FAM83F−/−) cells generated using CRISPR/Cas9 (Figs 3A, S3A, and S4B).
FAM83F also co-precipitated with CK1α in CK1α IPs from HCT116
FAM83F−/− cells that were stably rescued with FAM83FWT but not from
HCT116 FAM83F−/− cells rescued with FAM83FF284A/F288A mutant (Fig 3A).
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Figure 1. IMiDs degrade FAM83F but no other FAM83 proteins.
(A) MV4.11 cell extracts, treated with or without the IMiDs (10 μM for 24 h), were resolved by SDS–PAGE and subjected to Western blotting with the indicated antibodies.
(B) THP-1, HCT116, A549, DLD-1, PC-3, and HaCaT cell extracts treated with or without 10 μM lenalidomide for 24 h were resolved by SDS–PAGE and subjected to Western
blotting with the indicated antibodies. (C) THP-1, HCT116, A549, DLD-1, PC-3, and HaCaT cell extracts treated with or without IMiDs (10 μM for 24 h) were resolved by SDS–PAGE
and subjected to Western blotting with the indicated antibodies. (D) Densitometry of FAM83F and CK1α protein abundance upon treatment with the indicated IMiDs (10
μM for 24 h). FAM83F and CK1α protein abundances were normalised to GAPDH protein abundance and represented as fold change compared to untreated cells. Data
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The lenalidomide and pomalidomide-induced degradation of FAM83F
wasonly evident inHCT116wild-typeandHCT116 FAM83F−/− cells rescued
with FAM83FWT, but not in HCT116 FAM83F−/− cells or in HCT116 FAM83F−/−
cells rescuedwith FAM83FF284A/F288Amutant (Fig 3B and C). Overall, these
observations suggest that the interaction of FAM83F with CK1α is re-
quired for the IMiD-induced degradation of FAM83F (Fig 3B and C).
IMiD-induced FAM83F degradation is mediated via the
proteasome and is dependent on cereblon
IMiD-induced degradation requires the Cul4ACRBN E3 ligase complex
for the ubiquitylation of neo-substrates and subsequent proteaso-
mal degradation. Activation of Cul E3 ligases requires NEDDylation of
Cullin subunits. Thus, Cul E3 ligase activity can be blocked by
inhibiting the catalytic activity of the NEDD8-activating enzyme with
the smallmolecule inhibitor MLN4924 (Duda et al, 2008). Treatment of
cells with MLN4924 prevented lenalidomide and pomalidomide-
induced degradation of FAM83F in both DLD-1 and HCT116 cells,
indicating the requirement of a Cul E3 ligase for degradation (Fig 4A).
Inhibition of the proteasome with bortezomib, which leads to the
accumulation of mono- and poly-ubiquitylated proteins in cell ex-
tracts, also prevented lenalidomide and pomalidomide-induced
FAM83F degradation, indicating that the reduction in FAM83F pro-
tein ismediated by the proteasome (Fig 4A). To ascertain whether the
IMiD-induced degradation of FAM83F was dependent on CRBN, we
knocked out CRBN from DLD-1 cells using CRISPR/Cas9 genome
editing (Figs S3A–S5B). Lenalidomide and pomalidomide-induced
degradation of FAM83F evident in DLD-1 wild-type cells was com-
pletely abolished in DLD-1 CRBN−/− cells (Fig 4B and C). Restoration of
DLD-1 CRBN−/− cells with human FLAG-CRBN partially restored the
lenalidomide and pomalidomide-induced degradation of FAM83F.
However, when DLD-1 CRBN−/− cells were rescued with the FLAG-
CRBNV388I mutant, which mimics the mouse variant shown to be
inactive for IMiD-induced protein degradation as the IMiD is unable
to bind CRBNV388I (Kronke et al, 2015), lenalidomide and pomalido-
mide did not induce FAM83F degradation (Fig 4B and C). These
findings confirm that IMiD-induced FAM83F degradation requires the
Cul4ACRBN E3 ligase activity and is mediated by the proteasome.
FAM83G protects CK1α from IMiD-induced degradation
Lenalidomide-induced degradation of CK1α has been shown to be
robust in multiple myeloid cells (Kronke et al, 2015). In agreement,
we observed more robust degradation of CK1α upon lenalidomide
and other IMiD treatments in MV4.11 cells compared with DLD-1 cells
(Fig S6A and B) or a panel of other cancer cell lines (Figs 1 and S1).
Interestingly, the levels of most FAM83 proteins in MV4.11 cells were
either absent (FAM83B& F), ormuch lower in abundance (FAM83D, G
& H) compared with DLD-1 cells (Fig S6A). We hypothesised that the
absence of specific FAM83–CK1α complexes may explain why CK1α
degradation with lenalidomide was more robust in MV4.11 cells
compared with non-hematopoietic cell lines. To investigate whether
specific FAM83 proteins impact IMiD-induced CK1α degradation, we
generated HCT116 FAM83F−/− and FAM83G−/− cells with CRISPR/Cas9
genome editing (Figs S3–S5). Both lenalidomide and pomalidomide
treatment caused FAM83F degradation in HCT116 wild-type and
FAM83G−/− cells, whereas FAM83G levels remained unchanged upon
IMiD treatment in both HCT116 wild-type and FAM83F−/− cells (Fig 5A
and B). Lenalidomide reduced CK1α protein abundance in HCT116
wild-type, FAM83F−/−, and FAM83G−/− cell lines, but interestingly the
reduction in FAM83G−/− cells was slightly but significantly higher than
in wild-type cells (Fig 5A and B). In addition, thalidomide and
pomalidomide were also able to induce a more robust CK1α deg-
radation in FAM83G−/− cells compared with wild-type and FAM83F−/−
cells (Fig 5A and B). Considering this increased degradation is ob-
served with multiple IMiDs in FAM83G−/− cells, the possibility that, in
the absence of FAM83G, an increased proportion of CK1α binds to
FAM83F and is co-degraded as a complexwas tested. Indeed, whenwe
overexpressed wild-type GFP-FAM83G in HCT116 cells, pomalidomide-
induced degradation of FAM83F was partially rescued suggesting that
less CK1α is bound to FAM83F with CK1α preferentially binding to GFP-
FAM83G (Fig 5C–F). Thus, FAM83F is partially protected from degra-
dation. Indeed, overexpression of GFP-FAM83GF296A, which has min-
imal interaction with CK1α (Fig 5C and D) (Fulcher et al, 2018) in HCT116
cells was unable to reduce the pomalidomide-induceddegradation of
FAM83F (Fig 5E and F). However, it must be noted that these changes in
protein abundance are only slight and not statistically significant,
which is unsurprising as CK1α exists in multiple protein complexes,
including in other FAM83–CK1α complexes. Intriguingly, FAM83G was
identified by mass spectrometry as one of the top interactors of
overexpressed CRBN upon IMiD treatment (Kronke et al, 2014). This
would suggest that multiple CK1α–FAM83 complexes could be recruited
to the Cul4ACRBN complex after exposure to IMiDs, but only the CK1α–
FAM83F complex is positioned in such a way that ROC1 can ubiquitylate
both CK1α and FAM83F.
BTX161 is an efficient CK1α-degrader which reduces FAM83G
protein abundance through FAM83G–CK1α co-stability
The success of lenalidomide and pomalidomide in multiple mye-
loma treatment has led to the continuing development of new IMiD
derivatives. BTX161 has been reported to be the most efficient CK1α
degrader to date (Minzel et al, 2018). We compared BTX161 with
other IMiD compounds and confirmed the potency of BTX161 in CK1α
degradation in MV4.11 and DLD-1 cells (Fig S6A and B). We sought to
establish the effect of BTX161 on FAM83 protein stability using
HCT116, DLD-1, and MV4.11 cells (Fig 6A and B). We observed BTX161-
induced degradation of FAM83F in DLD-1 and HCT116 cells (Figs 6A
and B and S6A). FAM83F and CK1α degradation in these cells oc-
curred in a time and dose-dependentmanner with optimal degradation
presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. (E) HCT116 cell extracts, treated with 10 μM IMiDs for 6, 16, or 24 h, were
resolved by SDS–PAGE and subjected to Western blotting with the indicated antibodies. (F) HCT116 cell extracts, treated with 0.1, 1 or 10 μM of IMiDs for 24 h, were resolved
by SDS–PAGE and subjected to Western blotting with the indicated antibodies. Statistical analysis of data was completed using a Student’s unpaired t test and comparing
fold change between untreated and IMiD treated samples. Statistically significant P-values are denoted by asterisks (* < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001).
Source data are available for this figure.
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observed after treatment with 10 μM BTX161 for 24 h (Fig 6A and B). CK1α
degradation was even more substantial in MV4.11 cells, which do not
contain detectable levels of FAM83F protein (Figs 6A and B and S6A and
B). We quantified protein levels of CK1α, FAM83F, FAM83H, FAM83G, and
FAM83B via Western blot analysis after treatment of HCT116, DLD-1, and
MV4.11 cells with 10 μM BTX161 for 24 h (Fig 6C). FAM83F and CK1α
abundances were consistently reduced in all cell lines. FAM83H protein
abundance was slightly reduced in HCT116 and MV4.11 cells. FAM83B
protein abundance was unaffected by BTX161 treatment in all cells.
FAM83G protein abundance was slightly reduced in DLD-1 cells but
almost fully depleted in MV4.11 cells, whereas protein levels in HCT116
cells appear unchanged (Fig 6C). We confirmed that this strong FAM83G
degradation observed in MV4.11 cells was specific for BTX161 and, to a
lesser extent, lenalidomide treatments (Fig S7).
Given that the reductions in FAM83G protein abundance in
various cell lines mirror the reduction in CK1α protein, we queried
whether the FAM83G–CK1α complex is co-degraded by BTX161,
similarly to the FAM83F–CK1α complex, or if this was a result of
CK1α-dependent stability of FAM83G. CK1α protein was reduced in
HCT116 and DLD-1 cells using CK1α-targeting siRNA (siCK1α) (Fig 6D
Figure 2. FAM83F and CK1α protein abundance is
reduced at the plasma membrane upon IMiD
treatment.
(A) Wide-field immunofluorescence microscopy of
HCT116 GFP/GFPFAM83F knock-in cells, treated with or
without 10 μM pomalidomide for 24 h, stained with
antibodies recognising GFP (far left panels, green), and
CK1α (second row of panels from left, magenta) as
well as DAPI (third row of panels from left, blue).
Overlay of GFP, CK1α, and DAPI images as a merged
image is shown on the right. Immunofluorescence
images were captured with a 60× objective. Scale bar
represents 10 μm. Two representative images for each
staining are shown. (B) Specific subcellular fractions
from cytoplasmic, nuclear, and membrane
compartments from DLD-1 wild-type and FAM83F−/−
cells treated with or without 10 μM pomalidomide for
24 h, were resolved by SDS–PAGE and subjected to
Western blotting with the indicated antibodies.
Specificity of cytoplasmic, nuclear and membrane
fractions were determined with Western blotting with
compartment specific antibodies: α-tubulin
(cytoplasmic), Lamin A/C (nuclear), and Na/K-
ATPase (membrane).
Source data are available for this figure.
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Figure 3. IMiD-induced degradation of FAM83F requires interaction with CK1α.
(A) HCT116 wild-type, HCT116 FAM83F−/−, HCT116 FAM83F−/− rescued with FAM83FWT, and HCT116 FAM83F−/− rescued with FAM83FF284A/F288A cell extracts were subjected to
immunoprecipitation (IP) with anti-CK1α antibody. Input extracts and CK1α IP elutes were resolved by SDS–PAGE and subjected to Western blotting with the indicated
antibodies. (B) As in (A), except the cells were treated with IMiDs (10 μM for 24 h) as indicated and then were resolved by SDS–PAGE and subjected to Western blotting with
the indicated antibodies. (C) Densitometry of FAM83F and CK1α protein abundance upon treatment with IMiDs (10 μM for 24 h) from (B). FAM83F and CK1α protein
abundance was normalised to GAPDH protein abundance and represented as fold change compared to untreated cells. Data presented as scatter graph illustrating
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and E). This produced an ~75–80% reduction in CK1α protein after 48
h and resulted in a significant reduction in FAM83G protein when
compared with non-targeting siRNA controls (Fig 6D and E). Loss of
CK1α, caused by either BTX161 treatment or siRNA, resulted in re-
duced FAM83G protein levels suggesting some form of co-stability
between the two proteins. In contrast, FAM83F protein levels were
unaffected by siRNA treatment. We therefore propose that only
FAM83F–CK1α complex can be degraded by lenalidomide, poma-
lidomide, and BTX161 but the loss of CK1α by lenalidomide and
BTX161 can result in a reduction in FAM83G due to co-stability. The
efficiency of CK1α degradation by IMiDs varies between cell lines
and may be affected by the abundance of FAM83 proteins, some of
which may protect CK1α from IMiD-induced degradation and thus
the abundance of specific FAM83 proteins in cells could predict the
efficacy of overall CK1α degradation.
Inducible degradation of FAM83F attenuates Wnt signalling
We have recently established that FAM83F mediates canonical Wnt
signalling through association with CK1α (Dunbar et al, 2020). Ab-
lation of FAM83F significantly inhibits Wnt signalling in multiple cell
lines. The plasmamembrane localisation of FAM83F mediated by its
C-terminal farnesylation is also essential for its role in Wnt sig-
nalling (Dunbar et al, 2020). Hyperactivated Wnt signalling caused
by a truncation of adenomatous polyposis coli (Apc) is a hallmark of
colorectal cancer initiation and thus we sought to determine if
IMiD-induced FAM83F degradation could dampen down Wnt sig-
nalling in DLD-1 cells, which harbour a truncated Apc mutant
protein (Yang et al, 2006). We sought to evaluate the ability of
pomalidomide to reduce Wnt signalling in Apc mutant cells by
assessing the abundance of a Wnt-target gene, Axin2 (Jho et al,
2002), in DLD-1 wild-type, FAM83F−/−, and CRBN−/− cells following
pomalidomide treatment (Fig 7A). In addition, IMiD treatment of
DLD-1 cells efficiently reduced FAM83F, but not CK1α protein levels
(Fig 1C and D). Treatment of DLD-1 cells with 10 μM pomalidomide
for 48 h significantly reduced Axin2 mRNA abundance in wild-type
cells. Pomalidomide treatment did not alter Axin2 mRNA abun-
dance in DLD-1 FAM83F−/− or DLD-1 CRBN−/− cells indicating that the
pomalidomide-induced reduction in Axin2 mRNA requires FAM83F
and CRBN. To confirm that treatment with pomalidomide could
replicate all phenotypes associated with genetic knockout of
FAM83F, membrane fractions from DLD-1 wild-type, FAM83F−/− and
CRBN−/− cell lines treated with 10 μM pomalidomide for 24 h were
assessed for FAM83F and CK1α protein abundance (Fig 7B). In DLD-1
wild-type cells, membranous FAM83F and CK1α protein abundance
was reduced upon pomalidomide treatments, whereas no changes
were detected in DLD-1 CRBN−/− cells. CK1α levels in membrane
fractions of DLD-1 FAM83F−/− cells, which were already reduced
under untreated conditions compared with DLD-1 wild-type cells,
were not altered upon pomalidomide treatment.
To determine if pomalidomide could also reduce Wnt signalling
in cell lines containing no activating Wnt signalling mutations, we
treated HaCaT, HEK-293, and A549 cell lines with pomalidomide and
measured Axin2mRNA expression and FAM83F protein degradation
(Fig 7C and D). Pomalidomide treatment significantly reduced basal
Axin2 mRNA and FAM83F protein expression in HaCaT cells (Fig 7C
and D). Pomalidomide treatment increased basal Axin2 mRNA
expression in HEK-293 cells with no effect in A549 cells (Fig 7C and
D). Interestingly, HEK-293 and A549 cells do not express detectable
levels of FAM83F protein suggesting that the pomalidomide re-
duction in Axin2 transcript expression requires FAM83F protein (Fig
7C and D). These results demonstrate that IMiD-induced degra-
dation of FAM83F protein replicates the phenotypes observed with
genetic FAM83F-knockout cells in two distinct cell lines and, im-
portantly, IMiD-induced degradation of FAM83F appears to reduce
Wnt activity in colorectal cancer cells displaying constitutively
active Wnt signalling.
Discussion
Lenalidomide (Revlimid) was the second highest grossing pre-
scription drug worldwide in 2018 and with clinical trials for addi-
tional haematological derived cancers ongoing, the prominence of
IMiDs are likely to increase further (Urquhart, 2019). Therefore, the
discovery of novel proteins targeted for IMiD-induced degradation
is important to predict both unforeseen consequences of IMiD
treatments and potential new therapeutic targets. The inducible
degradation of CK1α, upon lenalidomide or BTX161 treatment, has
been established previously (Kronke et al, 2015; Minzel et al, 2018)
(Fig 8A). Here, we report that several IMiD compounds can induce
degradation of the FAM83F protein and demonstrate that degra-
dation of FAM83F requires its ability to interact with CK1α, indicating
that IMiD-induced recruitment of CK1α to CRBN mediates the co-
recruitment of FAM83F (Fig 8B). The specific degradation of FAM83F
and the absence of degradation of other FAM83 proteins, after
treatment with IMiD compounds, has been corroborated by
quantitative mass spectrometry (Donovan et al, 2018). It remains
unknown whether all FAM83–CK1α complexes are recruited to the
Cul4ACRBN complex upon IMiD treatment but not all complexes are
ubiquitylated and degraded. Alternatively, the binding of certain
FAM83 proteins to CK1α could restrict the recruitment of CK1α to
CRBN. However, given that FAM83G was reported as one of the top
binders of CRBN from cells treated with lenalidomide (Kronke et al,
2014), the former hypothesis appears more likely. Intriguingly, we
did observe a slight reduction in FAM83G protein abundance after
BTX161 treatment. However, given the substantial CK1α degradation
observed upon BTX161 treatment and that knockdown of CK1α
through siRNA reduces FAM83G abundance, these observations on
FAM83G protein stability are likely a result of FAM83G-CK1α co-
stability rather than direct degradation of the FAM83G–CK1α
complex (Fig 8C).
Increasingly, targeted protein degradation is being used as an
investigative tool in cell biology, with hopes to translate into a
individual data points with an overlay of themean ± SD. Statistical analysis of data was completed using a Student’s unpaired t test and comparing fold change between
untreated and IMiD treated samples. Statistically significant P-values are denoted by asterisks (* < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001).
Source data are available for this figure.
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therapeutic option for a variety of diseases (Roth et al, 2019). The
efficacy of inducible protein degradation is influenced by a number
of factors including protein synthesis rate, binding affinity of protein
of interest to E3 ligase complexes, efficiency of ubiquitylation and
presence of deubiquitinases (Schapira et al, 2019). Ubiquitylation
requires accessible lysine residues in close proximity to the E3 ligase
(Hershko&Ciechanover, 1992). Different IMiDs bind neo-substrates at
slightly different angles, thus presenting different residues to the
Figure 4. IMiD-induced FAM83F
degradation occurs via the
proteasome and is dependent on
cereblon.
(A) DLD-1 and HCT116 cell extracts
treated with 10 μM IMiDs, 1 μMMLN4924,
and 5 μM Bortezomib or a combination
thereof as indicated for 24 h were
resolved by SDS–PAGE and subjected to
Western blotting with the indicated
antibodies. The accumulation of HIF-
1α and ubiquitylated proteins following
MLN4924 and Bortezomib treatments,
respectively were used as positive
controls for successful compound
treatments. (B) DLD-1 wild-type, DLD-1
CRBN−/−, DLD-1 CRBN−/− rescued with
FLAG-CRBN, and DLD-1 CRBN−/− rescued
with FLAG-CRBNV388I cell extracts
treated with IMiDs (10 μM for 24 h),
were resolved by SDS–PAGE and
subjected to Western blotting with
the indicated antibodies. (C)
Densitometry of FAM83F protein
abundance upon treatment with IMiDs
(10 μM for 24 h) from (B). FAM83F
protein abundance was normalised to
GAPDH protein abundance and
represented as fold change
compared with untreated cells. Data
presented as scatter graph illustrating
individual data points with an
overlay of the mean ± SD. Statistical
analysis of data was completed using a
Student’s unpaired t test and
comparing fold change between
untreated and IMiD treated samples.
Statistically significant P-values are
denoted by asterisks (* < 0.05, ** < 0.01,
*** < 0.001, **** < 0.0001).
Source data are available for this
figure.
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Figure 5. FAM83G protects CK1α from IMiD-induced degradation.
(A) HCT116 wild-type, HCT116 FAM83F−/− and HCT116 FAM83G−/− cell extracts treated with IMiDs (10 μM for 24 h) were resolved by SDS–PAGE and subjected to Western
blotting with indicated antibodies. (B) Densitometry of CK1α protein abundance upon treatment with IMiDs in HCT116 wild-type, HCT116 FAM83F−/−, and HCT116 FAM83G−/− cells
from (A). CK1α protein abundance was normalised to GAPDH protein abundance and represented as fold change compared to untreated cells. Data presented as scatter graph
illustrating individual data points with an overlay of the mean ± SD. (C) HCT116 wild-type, HCT116 wild-type transfected with GFP-FAM83G and HCT116 wild-type transfected
with GFP-FAM83GF296A cell extracts were subjected to IP with anti-CK1α antibody. Input extracts, and indicated IP elutes were resolved by SDS–PAGE and subjected to Western
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ROC1 E3 ligase which may explain the differences in protein deg-
radation noted between various IMiD compounds (Sievers et al, 2018).
However, numerous unresolvedquestions remain regarding targeted
proteolysis, including how the formation of different protein com-
plexes affects degradation kinetics and/or occurrence. With our data,
we make important observations suggesting that the architecture of
CK1α in different FAM83–CK1α complexes most likely determines
whether, and to what extent, CK1α and the associated FAM83 protein
can be degraded by IMiDs. Specifically, the FAM83F–CK1α complex is
robustly degraded by various IMiD compounds, whereas seques-
tering CK1α in the FAM83G–CK1α complex spares CK1α from IMiD-
induced degradation.
Clinically, lenalidomide treatment in del(5q) MDS patients was
shown to be effective, and it was suggested that this might be due to
haploinsufficiency of CK1α (Kronke et al, 2015). We propose that the
efficiency of CK1α degradation is rather influenced by the relative
abundance of FAM83 proteins. We observe substantial lenalidomide-
induced CK1α degradation in MV4.11 cells, which lack expression of
several FAM83 proteins, but not in any other cell line which displays
higher abundance of FAM83 proteins. Therefore, we hypothesise that
lenalidomide can facilitate the degradation of the non-FAM83 bound
pool of CK1α as well as the FAM83F-bound pool and thus the
abundance of other FAM83 proteins in cells may be used as pre-
dicting biomarkers for levels of IMiD-induced CK1α degradation,
which may inform the use of lenalidomide for targeting CK1α. In
addition to IMiDs, other target protein degraders such as PROTACs
are emerging as key therapeutic modalities in drug research (Paiva &
Crews, 2019). Our observations presented in this study clearly il-
lustrate that the nature of the inherent complex in which the target
protein exists is an important factor that determines whether the
target protein can be degraded. This not only provides challenges in
trying to design degraders of specific target proteins that yield
complete degradation but also provide opportunities in which
specific protein complexes can be targeted for degradation, thereby
affecting specific functions of target proteins. In this regard, the
efficacy for a protein degrader should perhaps not be judged by how
much a target protein is degraded but rather to what extent a change
in expected phenotype is achieved. Indeed, for proteinswhich exist in
distinct functional pools, specific degradation of subcomplexes may
be sufficient to disrupt target pathways, while leaving other non-
targeted subcomplex functions intact.
FAM83F has been implicated in oncogenesis with high FAM83F
expression observed in oesophageal squamous cell carcinoma
(Mao et al, 2016), lung adenocarcinoma (Fan et al, 2019), glioma (Xu
et al, 2018), and thyroid carcinoma (Fuziwara et al, 2019). In contrast,
FAM83F has been reported to enhance the stabilisation and activity
of the tumour suppressor p53 with siRNA targeting FAM83F reducing
cellular proliferation (Salama et al, 2019). These effects are dependent
on the mutational status of p53 with overexpression of FAM83F in-
creasing cell migration in cells containing mutant p53, indicating
FAM83F may promote or inhibit cancer progression depending on the
tumour’s mutational status. Recently, we have demonstrated that the
membranous FAM83F–CK1α complex activates canonical Wnt sig-
nalling (Dunbar et al, 2020). Activated Wnt signalling is a hallmark of
many cancers, especially colorectal cancers (CRCs) (Network, 2012).
However, it is often believed that genetic alterations which activate
canonical Wnt signalling in sporadic CRCs, specifically those at the
level of the β-catenin destruction complex, will render any inhi-
bition of upstream membranous Wnt signalling proteins ineffectual
(Kahn, 2014). In contrast to this, we demonstrate that reducing
membrane-associated FAM83F–CK1α with IMiD treatment can modu-
late canonical Wnt signalling in DLD-1 cells, which contain mutant Apc
and are unresponsive to Wnt3A stimulation. Although there are
benefits to testing the ability of IMiD-induced FAM83F degradation to
attenuate Wnt signalling in cells containing Wnt activating mutations,
the presence of truncated Apc adds increased complexity. Apc is a key
component of the β-catenin destruction complex which regulates the
canonical Wnt signalling pathway by regulating levels of the effector
protein,β-catenin, and is required forWnt signalosome formation after
Wnt ligand binding (Clevers & Nusse, 2012; Parker &Neufeld, 2020). The
presence of an Apc truncation mutation disrupts this complex to such
an extent as to increase Wnt signalling but not completely abolish the
complex, so that in DLD-1 cells, truncated Apc can still interact with
other components of the β-catenin destruction complex and phos-
phorylation of β-catenin (S45) by CK1α is still present (Yang et al, 2006;
Li et al, 2012). Therefore, there are caveats to be considered when
evaluating Wnt signalling effects induced by removal of FAM83F–CK1α
complexes in these cell lines. Lenalidomide has been tested in phase I
and phase II clinical trials for sporadic CRCs but clinical response has
been poor (Siena et al, 2013). Often these trials are in advanced
metastatic tumours which contain multiple oncogenic driver muta-
tions and aberrant signalling pathways. The clinical effect of IMiDs on
an early Wnt-dependent disease such as the initial polyp formation in
familial adenomatous polyposis, which is caused by mutant Apc
(MacDonald et al, 1992), may yield more promising results.
Materials and Methods
Plasmids
All constructs are available for request from the Medical Research
Council-Protein Phosphorylation and Ubiquitylation Unit (MRC-
PPU) reagents website (http://mrcppureagents.dundee.ac.uk).
blotting with the indicated antibodies. (D) Densitometry of FAM83F and FAM83G protein abundance in anti-CK1α IP elute from (C). FAM83F and FAM83G protein abundances
werenormalised to CK1α protein abundance and represented as fold change comparedwith un-transfectedHCT116 wild-type cells. Data presented as scatter graph illustrating
individual data points with an overlay of themean ± SD. (E) As in (C), except the cells were treatedwith IMiDs (10 μM for 24 h) as indicated and then were resolved by SDS–PAGE
and subjected to Western blotting with the indicated antibodies. (F) Densitometry of FAM83F protein abundance upon treatment with IMiDs from (E). FAM83F protein
abundance was normalised to GAPDH protein abundance and represented as fold change compared to untreated cells. Data presented as scatter graph illustrating individual
data points with an overlay of themean ± SD. (B, F) Statistical analysis of (B) and (F) data was completed using a Student’s unpaired t test and comparing fold change between
untreated and IMiD treated samples. Statistically significant P-values are denoted by asterisks (* < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001).
Source data are available for this figure.
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Figure 6. BTX161 is an efficient CK1α-degrader which reduces FAM83G protein abundance through FAM83G-CK1α co-stability.
(A)HCT116, DLD-1, and MV4.11 cell extracts treated with varying concentrations of BTX161 (0, 0.1, 1, or 10 μM) for 24 h were resolved by SDS–PAGE and subjected toWestern
blotting with the indicated antibodies. (B) As in (A) except cells were treated with 10 μM BTX161 for varying times (0, 6, 16 or 24 h) prior to lysis. (C) Densitometry of FAM83H,
FAM83G, FAM83F, FAM83B, and CK1α protein abundance from (A, B) after treatment with 10 μM BTX161 for 24 h. Protein of interest abundance was normalised to GAPDH
protein abundance and represented as fold change compared to untreated cells. Data presented as scatter graph illustrating individual data points with an overlay of
themean ± SD. The dashed line indicates a fold change of one which is equivalent to an untreated sample. Statistical analysis was completed using a Student’s unpaired t
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The unique identifier (DU) numbers provide direct links to the
cloning strategy and sequence information. Sequences were ver-
ified by the DNA sequencing service, University of Dundee (http://
www.dnaseq.co.uk). Constructs generated include pBABED.puro
FAM83F (DU37979), pBABED.puro FAM83FF284A/F288A (DU28196),
pBABED.puro FLAG CRBN (DU54685), pBABED.puro FLAG CRBNV388I
(DU64137), pBABED.puro U6 FAM83F tv1 Nter KI sense (DU54050),
pX335 FAM83F Nter KI Antisense (DU54056), pMS-RQ FAM83F Nter
GFP donor (DU54325), pBABED.puro U6 FAM83F ex2 KO sense
(DU54848), pX335 FAM83F ex2 KO Antisense (DU54850), pBABED.puro
U6 CRBN ex3 KO sense A (DU64046), pX335 CRBN ex3 KO Antisense A
(DU64483), pBABED.puro U6 FAM83G ex2 KO sense (DU52480), pX335
FAM83G ex2 KO Antisense (DU52484), pcDNA5-FRT/TO-GFP-FAM83G
(DU33272), and pcDNA5-FRT/TO-GFP-FAM83GF296A (DU28477).
Plasmid amplification was completed by transforming 10 μl Escher-
ichia coli DH5α competent cells (Invitrogen) using 1 μl of plasmid DNA.
Bacteriawere incubated on ice for 10min before heat-shocking at 42°C
for 45 s. After a further 2 min on ice, the transformed bacteria were
plated on LB agar medium plates containing 100 μg/ml ampicillin and
incubated at 37°C for 16 h. Single colonieswere used to inoculate a 5ml
culture of LB medium containing 100 μg/ml ampicillin then incubated
at 37°C for 16 hwith constant shaking. Plasmid DNAwas purified froma
bacterial culture using QIAGEN Miniprep Kit by following the manu-
facturer’s protocol. Isolated DNA yield was quantified using a Nano-
Drop 1000 spectrophotometer (Thermo Fisher Scientific).
Antibodies
Antibodies recognising FAM83B (SA270), FAM83D (SA102), FAM83F (SA103),
FAM83H (SA273), CK1α (SA527), CK1ε (SA610), CK1δ (SA609), and GFP (S268B)
were generated in-house and are available for request from the MRC-PPU
reagents website (http://mrcppureagents.dundee.ac.uk). Antibodies rec-
ognising GAPDH (14C10) (#2118), IKZF1 (D6N9Y) (#14859), CRBN (D8H3S)
(#71810), Na, K-ATPase alpha1 (D4Y7E) (#23565), and Lamin A/C (#2032) were
obtained from Cell Signalling Technology. Additional antibodies used were
FAM83G (ab121750; Abcam),α-tubulin (MA1-80189; ThermoFisher Scientific),
Ubiquitin (BML-PW8810; Enzo), HIF-1α (6109590; BD Biosciences), and ZFP91
(A303-245A; Bethyl Laboratories). Secondary antibodies used were Star-
Bright Blue 700 goat anti-rabbit IgG (12004161; Bio-Rad), StarBright Blue 700
goatanti-mouse IgG (12004158; Bio-Rad), IRDye800CWdonkeyanti-goat IgG
(926-32214; LI-COR) and IRDye 800CW goat anti-rat IgG (926-32219; LI-COR).
Cell culture
THP-1 (TIB-202; ATCC) and MV4.11 (CRL-9591; ATCC) cells were main-
tained in Roswell Park Memorial Institute 1640 medium (RPMI; Gibco).
HCT116 (CCL-247; ATCC), DLD-1 (CCL-221; ATCC), PC-3 (CRL-1435; ATCC),
A549 (CCL-185; ATCC), U2OS (HTB-96; ATCC), HEK-293 (CRL-1573; ATCC),
ARPE-19 (CRL-2302; ATCC), SH-SY5Y (CRL-2266; ATCC), G-361 (CRL-1424;
ATCC), SK-MEL-13 (RRID:CVCL_6022), HaCaT (from Joan Massague’s lab
at Memorial Sloan Kettering Cancer Centre, not commercially obtained
but can be provided on request) (Sapkota et al, 2007), and HEK-293-FT
(R70007; Thermo Fisher Scientific) cells were maintained in DMEM
(Gibco). RPMI and DMEM were supplemented with 10% (vol/vol) FBS
(F7524; Sigma-Aldrich), 2mM L-glutamine (25030024; Invitrogen), 100 U/
ml penicillin, and 100 mg/ml streptomycin (15140122; Invitrogen). Cells
lines were regularly tested for mycoplasma contamination and only
mycoplasma-free cell lines were used for experimentation.
Generation of GFP/GFPFAM83F, FAM83F2/2, CRBN2/2, and
FAM83G2/2 cell lines using CRISPR/Cas9 genome editing
All CRISPR/Cas9 targeting procedures were performed using a dual
guide nickase strategy. For the generation of FAM83F knockout HCT116
and DLD-1 cell lines, the FAM83F locus was targeted with sense guide
RNA (pBabeD-puro vector, DU54848); GCGTCCAGGATGATGTACACT and
antisense guide RNA (pX335-Cas9-D10A vector, DU54850); GGCAGGAGT-
GAAGTATTTCC. For the generation of CRBN knockout DLD-1 cell lines, the
CRBN locus was targeted with sense guide RNA (pBabeD-puro vector,
DU64046); GCTCAAGAAGTCAGTATGGTG and antisense guide RNA (pX335-
Cas9-D10A vector, DU64483); GTGAAGAGGTAATGTCTGTCC. For the gen-
eration of FAM83G knockout HCT116 cell lines, the FAM83G locus was
targeted with sense guide RNA (pBabeD-puro vector, DU52480);
GGACCGCTCCATCCCGCAGC and antisense guide RNA (pX335-Cas9-
D10A vector, DU52484); GCTGGGGCCAGTACTCCAGGG. For generation
of N-terminal GFP knock-in to the FAM83F locus, the FAM83F locus
was targeted with sense guide RNA (pBabeD-puro vector, DU54050);
GTTCAGCTGGGACTCGGCCA, antisense guide RNA (pX335-Cas9-D10A
vector, DU54056); GCGAGGCGCACGTGAACGAGA and the GFP-FAM83F
donor (pMK-RQ vector, DU54325).
Plasmids (1 μg of sense and antisense guide RNAs + 3 μg donor for
knock-ins) were diluted in 1 ml OptiMem (Gibco) and 20 μl of poly-
ethylenimine (PEI; 1 mg/ml) (Polysciences) was added. This transfection
mix was vortexed vigorously for 15 s, incubated for 20 min at room
temperature and then added dropwise to a 10-cm diameter dish
containing ~70% confluent cells in complete culture medium. Selection
of transfected cells was performed 24 h post transfection in medium
containing 2 μg/ml puromycin for 48 h. Single cells were isolated by
FACS, with single GFP-positive cells (for knock-ins) or all cells (for
knockouts) isolated, and plated into individual wells of 96-well plates,
pre-coated with 1% (wt/vol) gelatin (Sigma-Aldrich). Viable clones were
expanded and assessed for successful knock-in or knockout by both
Western blotting and genomic DNA sequencing (Figs S3–S5).
For verification by DNA sequencing, the region surrounding the
gRNA target siteswere amplified by PCRwith KODHot Start Polymerase
(Merck) according to manufacturer’s instructions with the following
test and comparing fold change between untreated and samples treated with 10 μM BTX161 for 24 h. (D) HCT116 and DLD1 cell extracts transfected with control siRNA or
siCK1α for 48 h were resolved by SDS–PAGE and subjected toWestern blotting with the indicated antibodies. (E) Densitometry of CK1α, CK1δ, CK1ε, FAM83H, FAM83G, FAM83F,
FAM83D and FAM83B protein abundance from (D) normalised to GAPDH protein abundance and represented as fold change compared to HCT116 and DLD-1 cells
transfected with Non-targeting siRNA control. Data presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. The dashed line
indicates a fold change of one which is equivalent to an untreated sample. Statistical analysis was completed using a Student’s unpaired t test and by comparing fold
change between cells transfected with Non-targeting siRNA control and cells transfected with siCK1α. Statistically significant P-values are denoted by asterisks (* < 0.05, **
< 0.01, *** < 0.001, **** < 0.0001).
Source data are available for this figure.
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Figure 7. IMiD-induced degradation of FAM83F attenuates Wnt signalling and removes CK1α from the plasma membrane.
(A) qRT-PCR was performed using cDNA from DLD-1 wild-type, DLD-1 FAM83F−/− and CRBN−/− cell lines following treatment with 10 μM pomalidomide for 48 h, and
primers for Axin2 and GAPDH genes. Axin2 mRNA expression was normalised to GAPDH mRNA expression and represented as arbitrary units. Data presented as scatter
graph illustrating individual data points with an overlay of the mean ± SD. (B) Membrane fractions from DLD-1 wild-type, DLD-1 FAM83F−/−, and DLD-1 CRBN−/− cell lines,
following treatment with 10 μM pomalidomide for 24 h, were resolved by SDS–PAGE and subjected to Western blotting with the indicated antibodies. The specificity of
membrane compartment isolation was determined with Western blotting for Na/K ATPase, a membrane specific protein. (C) qRT-PCR was performed using cDNA derived
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primer pairs: FAM83F exon 2 (Forward: TCATTGCTGTGGTCATGGAC, Re-
verse: AATCCGGAAGTCAGTGAGCT), FAM83F N-terminal GFP KI (Forward:
TGCGCGGAAAATGAACTCGTACC, Reverse: GTAGAAACCAGTGTCCGTCCAGC),
CRBN exon 3 (Forward: GGTGCTGATATGGAAGAATTTCATGGC, Reverse:
GTATGAAGGTGAAGAGCTGAGTTAGATGG) and FAM83G exon 2 (Forward:
TCTTTCCCGCAGATTGCTCATGG, Reverse: TTCTTCTGGGGAACCAGAAACACC).
PCR products of positive clones were cloned with the StrataClone PCR
Cloning Kit (Agilent) into the supplied vector system, according to the
manufacturer’s protocol. Sequencing of the edited loci in the positive
clones was performed by the MRC-PPU DNA sequencing and services
(http://mrcppureagents.dundee.ac.uk).
Transient transfections
Transient transfections were performed in HCT116 cells with either
pcDNA5-FRT/TO-GFP-FAM83G (DU33272) or pcDNA5-FRT/TO-GFP-
FAM83GF296A (DU28477). Plasmids (1 μg) were diluted in 1 ml OptiMem
(Gibco) and 20 μl PEI (1 mg/ml) was added. The transfection mix was
incubated for 20min at room temperature, then added dropwise to a
10-cm2 diameter dish of cells in complete culture medium. Fresh
media was added 24 h post-transfection and indicated treatments
performed thereafter.
Retroviral transductions
Retroviruses were produced using the following constructs: pBA-
BED.puro FAM83FWT (DU37979), pBABED.puro FAM83FF284A/F288A (DU28196),
pBABED.puro FLAG CRBN (DU54685), and pBABED.puro FLAG CRBNV388I
(DU64137). Retroviruses were produced by transfecting HEK-293-FT cells
as previously described (Fulcher et al, 2019). Briefly, 6 μg pBabe plasmid,
3.8 μg pCMV5-GAG/Pol (Clontech), and 2.2 μg pCMV5-VSV-G (Clontech)
were diluted in 600 μl OptiMem (Gibco) and 24 μl PEI (1 mg/ml) was
added. The transfection mixture was incubated for 20 min at room
temperature then added dropwise to a 10-cm diameter dish of cells in
from HaCaT, HEK-293 and A549 wild-type cell extracts following treatment with 10 μMpomalidomide for 48 h and a further treatment with either L-CM or Wnt3A-CM for 6
h before lysis, and primers for Axin2 and GAPDH genes. Axin2mRNA expression was normalised to GAPDHmRNA expression and is represented as fold change compared
with untreated cells. Data presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. (D) Extracts derived from HaCaT, HEK-293 and
A549 wild-type cells treated with 10 μM pomalidomide for 48 h were resolved by SDS–PAGE and subjected to Western blotting with indicated antibodies. Statistical
analysis of data was completed using a Student’s unpaired t test. Statistically significant P-values are denoted by asterisks (* < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001). n.s.,
non-significant.
Source data are available for this figure.
Figure 8. Proposed model for IMiD-induced FAM83F
and CK1α degradation.
(A) Previously reported mode of action for CK1α
degradation by lenalidomide and BTX161 compounds.
The IMiD can bind CK1α and a conserved binding
pocket in CRBN, thus bringing CK1α into proximity of
the Cul4ACRBN complex, facilitating the addition of
ubiquitin by ROC1 to CK1α. CK1α is then subsequently
degraded via the proteasome. (B) Our proposed model
for FAM83F degradation by multiple IMiDs. The IMiDs
can bind the CK1α–FAM83F complex and a conserved
binding pocket in CRBN, thus bringing the
CK1α–FAM83F complex into proximity of the Cul4ACRBN
complex, facilitating the addition of ubiquitin by
ROC1 to the CK1α–FAM83F complex. CK1α and FAM83F
are then subsequently degraded via the proteasome.
Mutation of FAM83F at F284 and F288 to alanines
abolishes the interaction with CK1α, thus there is no
recruitment or subsequent degradation of FAM83F
upon IMiD treatment. Mutation of CRBN at V388 to
isoleucine to mimic the mouse homolog which cannot
bind IMiDs prevents IMiD from binding to CRBN, thus no
IMiD neo-substrate, including the CK1α–FAM83F
complex, can be recruited to the Cul4ACRBN complex.
(C) We propose that the BTX161-induced reduction in
FAM83G protein abundance is a result of efficient
CK1α degradation by BTX161 resulting in a loss of
FAM83G protein due to FAM83G-CK1α co-stability, and
not direct BTX161-induced FAM83G degradation.
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complete culture medium. Fresh media was added 24 h post-
transfection. Media containing retroviruses was collected after 24 h
and passed through a 0.45 μm sterile syringe filter. For transduction of
target cells, 1 ml of retroviral medium together with 8 μg/ml polybrene
(Sigma-Aldrich) was added to a 10 cm diameter dish of cells containing
9 ml complete culture medium. Selection of transduced cells was
performed 24 h post transduction with cells incubated in media con-
taining 2μg/ml puromycin for 48h. Successful transductionwas assessed
by Western blotting.
Compound treatments
IMiD compounds (Thalidomide, Lenalidomide, Pomalidomide
and Iberdomide) were obtained from Caymen Chemicals. BTX161
compoundwas synthesised in-house and is available for request from
theMRC-PPU reagents website (http://mrcppureagents.dundee.ac.uk).
IMiD compounds were added to cell culture media at indicated
concentrations (between 0.1 and 10 μM) for indicated duration. dTAG-
13 (Sigma-Aldrich), a CRBN-binding PROTAC, was used at 1 μM for 24 h.
MLN4924 (Sigma-Aldrich), an inhibitor of NEDD8-activating E1 enzyme,
was used at 1 μM for 24 h. Bortezomib (Sigma-Aldrich), a proteasome
inhibitor, was used at 5 μM for 24 h.
Generation of L- and Wnt3A-conditioned medium (CM)
Mouse fibroblast L-cells (CRL-2648; ATCC) and mouse fibroblast
L-cells that stably overexpress Wnt3A (CRL-2647; ATCC) were
maintained in DMEM containing 10% FCS. To generate CM, L-cells
and L-Wnt3A cells were grown in DMEM in 15-cm diameter dishes for
3 d. Mediumwas collected, filtered (0.22 μm) and stored as L-CM and
Wnt3A-CM (Wnt3A-CM). Before treatment, CM was diluted 50:50 in
DMEM containing 10% FCS.
Cell lysis, SDS–PAGE, and Western blotting
Cells were washed and scraped in ice-cold PBS, and then pelleted.
For whole cell lysates, cell pellets were lysed in lysis buffer (20 mM
Tris–HCl [pH 7.5], 150mMNaCl, 1mMEDTA, 1mMEGTA, 1% [vol/vol] Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, and 1× complete EDTA-free protease inhibitor cocktail [Roche]).
Lysates were clarified at 17,000g for 20 min. Cellular fractionation into
cytoplasmic, nuclear and membrane lysates was completed using a
subcellular protein fractionation kit (Thermo Fisher Scientific) following
the manufacturer’s instructions. Briefly, cells were lysed in sequential
buffers to separate cellular compartments into cytoplasmic, membrane,
nuclear, and cytoskeletal fractions. Protein concentrationwasmeasured
using Pierce Coomassie Bradford Protein Assay Kit (Thermo Fisher
Scientific). Protein concentrations were adjusted to 1–3 μg/μl in lysis
buffer and NuPAGE 4× LDS sample buffer (NP0007) (Thermo Fisher
Scientific) was added to lysates. Lysates (15–30 μg protein) were sep-
arated by sodium dodecyl sulphate-polyacrylamide electrophoresis
(SDS–PAGE) and gels were transferred to nitrocellulose membranes.
After blocking in 5% (wt/vol) milk in TBS-T (50 mM Tris–HCL [pH 7.5], 150
mM NaCl, 0.1% [vol/vol] Tween-20) for 60 min, membranes were in-
cubated in primary antibody (1:1,000 dilution in blocking buffer) for 16 h
at 4°C,washed3× 10min in TBS-T, then incubated in secondary antibody
(1:5,000dilution inblockingbuffer) for 1hat roomtemperatureandwashed
3×10min inTBS-T. Fluorescenceof secondaryantibodywasdetectedusing
the Chemidoc system (Bio-Rad) and data analysed by Image lab software
(Bio-Rad). Densitometry of protein blots was completed using Image J
software (https://imagej.net). The density of protein of interest bandswere
measured and normalised to those of loading control bands with fold-
change calculations and statistical analysis performed using Microsoft
Excel software (www.microsoft.com). Graphical representations of data
were prepared using Prism 8 (www.graphpad.com).
Immunoprecipitation
Protein lysates were prepared, and protein concentration quan-
tified as previously outlined. Anti-CK1α antibody (1 μg) was added to
each lysate sample (1 mg protein) and incubated on a rotating
wheel for 16 h at 4°C. Protein G sepharose beads (DSTT) pre-
equilibrated in cell lysis buffer were added (20 μl of 50% beads:
lysis buffer slurry) to each lysate sample and incubated on a ro-
tating wheel for 1 h at 4°C. Beads were pelleted and supernatant
removed and stored as flow-through. Beads were washed in cell
lysis buffer three times. Elution was performed by the addition of 40
μl of NuPAGE 1× LDS sample buffer to the beads, followed by de-
naturing proteins at 95°C for 10 min. Input and eluted samples were
analysed by SDS–PAGE as previously described.
Immunofluorescence
Cells were plated on sterile glass coverslips. Cells were fixed in 4%
(vol/vol) paraformaldehyde for 15 min, permeabilized in 0.2% (vol/
vol) Triton X-100 for 10 min, and then blocked in 5% (wt/vol) bovine
serum albumin for 60min. Cells were incubated in primary antibody
(1:100) diluted in 0.5% (wt/vol) bovine serum albumin for 16 h at 4°C.
After washing in PBS/0.1% Tween-20, cells were incubated in Alexa
Fluor 594 secondary (1:500; Thermo Fisher Scientific) for 60 min at
room temperature. Coverslips were washed in PBS/0.1% Tween-20
and then incubated with 1 μg/ml DAPI (Sigma-Aldrich) for 5 min at
room temperature to visualise nuclei. Coverslips were mounted on
glass slides in Vectashield mounting media (Vector Laboratories)
and sealed with CoverGrip coverslip sealant (Biotium). Images were
captured on a DeltaVision microscope using 60× objectives. Images
were prepared using Omero software (www.openmicroscopy.org).
Transfection with siRNA
ON-TARGETplus human CSNK1A1 siRNA (L-003957-00-0005; Dhar-
macon) and ON-TARGETplus Non-targeting pool (D-001810-10-05;
Dharmacon) were resuspended using 5× siRNA buffer (B-002000-
UB-100; Dharmacon). Adherent cells were seeded in six-well plates
and grown to 70–80% confluence. siRNA was diluted in OptiMem
(Gibco) to a final working concentration of 25 pmol siRNA per well of
a six-well plate. Lipofectamine RNAi-MAX transfection reagent
(13778100; Thermo Fisher Scientific) was diluted in OptiMem to a
final working volume of 7.5 μl Lipofectamine per well. After incu-
bating both siRNA and Lipofectamine samples separately for 5 min
at room temperature, they were mixed and incubated for 20 min at
room temperature. The siRNA-Lipofectamine mixture was added
dropwise to cells and incubated for 48 h before lysis.
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Quantitative real-time PCR (qRT-PCR)
Cells were grown to ~70% confluence in six-well plates. Cells were then
treated with IMiD compounds as indicated before RNA extractions were
performedusing the RNeasyMini Kit (QIAGEN). RNAwasquantified using
a NanoDrop 3300 Fluorospectrometer (Thermo Fisher Scientific). Syn-
thesis of cDNAwas completed using iScript cDNA Synthesis Kit (Bio-Rad)
and 1 μg of RNA per reaction. qRT-PCRwas performed in triplicate in a 10
μl final volumewith 2 μM forward primer, 2 μM reverse primer, 50% (vol/
vol) iQ SYBR Green Supermix (Bio-Rad), and 2 μl cDNA (diluted 1:5) using
a CFX384 real-time system qRT-PCR machine (Bio-Rad). Primers were
designedusing Benchling andpurchased from Invitrogen. Axin2 forward:
TACACTCCTTATTGGGCGATCA, Axin2 reverse: TTGGCTACTCGTAAAGTTTTGGT,
GAPDH forward: TGCACCACCAACTGCTTAGC, GAPDH reverse: GGCATG-
GACTGTGGTCATGAG. The datasets were analysed using the comparative
Ct method (ΔΔCt Method) (Livak & Schmittgen, 2001) with Axin2 theWnt-
target gene and GAPDH the endogenous control gene. Statistical analy-
sis was performed using Microsoft Excel software (www.microsoft.com)
and graphical representations of data were prepared using Prism 8
(www.graphpad.com).
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000804.
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